Scientific consensus suggests that HIPK2 is a “bona fide” oncosuppressor protein, thus, its activation inhibits tumor growth, mainly by induction of apoptosis with p53 activation, while its inactivation increases tumorigenicity and chemoresistance through inhibition of apoptotic pathways or de-repression of pro-survival pathways [29]. Here, TP53 is linked to neoplasm.